Review ArticleReview Article
Pharmacology of Heparin and Related Drugs
Barbara Mulloy, John Hogwood, Elaine Gray, Rebecca Lever and Clive P. Page
David R. Sibley, ASSOCIATE EDITOR
Pharmacological Reviews January 2016, 68 (1) 76-141; DOI: https://doi.org/10.1124/pr.115.011247
Barbara Mulloy
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
John Hogwood
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
Elaine Gray
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
Rebecca Lever
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
Clive P. Page
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
David R. Sibley
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Pharmacy, London, United Kingdom (R.L.)
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
Pharmacology of Heparin and Related Drugs
Barbara Mulloy, John Hogwood, Elaine Gray, Rebecca Lever and Clive P. Page
Pharmacological Reviews January 1, 2016, 68 (1) 76-141; DOI: https://doi.org/10.1124/pr.115.011247
Jump to section
- Article
- Abstract
- I. Introduction
- II. History
- III. Structure of Heparin and Heparan Sulfate
- IV. Molecular Interactions of Heparin
- V. Analysis
- VI. Mechanism of Action of Anticoagulant Activity
- VII. Clinical Use as an Anticoagulant/Antithrombotic
- VIII. Non-Anticoagulant Effects of Heparin
- IX. Non-Anticoagulant Effects of Heparin: Preclinical and Clinical Studies
- X. Heparin in Biomaterials and Regenerative Medicine
- XI. Novel Drugs Based on the Non-Anticoagulant Actions of Heparin
- XII. Summary
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement